First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time 

January 25, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand

Date of Release: March 1, 2022

Expiration Date: March 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

Course Description:

In this session, Drs. Janessa Laskin and Laura Williamson will present a case of a 64-year-old female diagnosed with metastatic lung neuroendocrine carcinoma. She had been treated with chemotherapy and radiation, with some response but subsequent growth in multiple locations. Whole genome and transcriptome analysis of a metastatic chest wall mass was performed as part of the Personalized OncoGenomics Study. Molecular analysis revealed no targetable driver mutations and low tumour mutation burden, but gene expression signatures provided evidence for T cells and macrophages in the tumour sample. The combination of biomarkers made this patient eligible for an immunotherapy trial. An additional case with similar gene expression signatures, a pediatric chordoma patient found to have low tumour mutation burden but high tumour T cell infiltration, subsequently responded to immunotherapy. The use of whole genome and transcriptome profiling to examine the immune microenvironment and biomarkers for immunotherapy response will be reviewed. The design of an immunotherapy trial based on both DNA and RNA molecular markers will be discussed

Target Audience:

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic and VICC consortia, and ACMG.

Learning Objectives:

At the conclusion of this session, participants should be able to:

1. Describe the genomic methods used to care for this patient